F-star Therapeutics is a clinical-stage biopharmaceutical company. Co. is engaged in the discovery and development of therapeutics for the treatment of a range of cancers and inflammatory diseases. Co.'s STING (STimulator of INterferon Genes) product portfolio include STING agonist clinical program in oncology, STING antagonist compounds for inflammatory diseases, and STING agonist antibody drug conjugate program for oncology. Co. is developing its SB 11285, as an immunotherapeutic cyclic dinucleotide for the treatment of selected cancers. Co. is also exploring the use of its STING antagonist compounds for the treatment of certain autoimmune and inflammatory diseases. We show 9 historical shares outstanding datapoints in our FSTX shares outstanding history coverage, used to compute FSTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing FSTX market cap history over the course of time is important for investors
interested in comparing FSTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of FSTX versus a peer is one thing; comparing
FSTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like FSTX can fluctuate over the course of history.
With this page we aim to empower investors researching FSTX by allowing them to research the FSTX market cap history. |
Free FSTX Email Alerts:
Video: The Importance of Market Cap
